Dynavax Technologies
2100 Powell Street
Suite 300
Emeryville
California
94608
United States
Tel: 510-848-5100
Fax: 510-848-1379
Website: http://www.dynavax.com/
Email: contact@dynavax.com
About Dynavax Technologies
We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.
463 articles about Dynavax Technologies
-
Dynavax Technologies Corporation To Present At Bear Stearns Biotech West Coast Confab
3/21/2006
-
Dynavax Technologies Corporation Announces Fourth Quarter And Year-End 2005 Financial Results
3/16/2006
-
Dynavax Technologies Corporation Presents Positive TOLAMBA Phase 2/3 Results At American Academy of Allergy, Asthma and Immunology (AAAAI) Meeting
3/6/2006
-
Dynavax Technologies Corporation Announces Fourth Quarter 2005 Financial Results Conference Call And Webcast
3/3/2006
-
Dynavax Technologies Corporation Provides Update On TOLAMBA Program; Company To Conduct Additional Major Safety And Efficacy Trial
3/2/2006
-
Dynavax Technologies Corporation Announces Board Of Directors Changes
2/24/2006
-
Dynavax Technologies Corporation To Present Data On Phase 2/3 Clinical Trial Of TOLAMBA At AAAAI 2006
2/15/2006
-
Dynavax Technologies Corporation To Present At Two Focus Sessions At Biotechnology Industry Organization (BIO) CEO & Investor Conference February 15, 2006
2/9/2006
-
Dynavax Technologies Corporation To Participate In Webcast Hosted By Pacific Growth Equities, LLC
1/25/2006
-
The Day In Review: Good Data From Novartis Corporation And Dynavax Technologies Corporation
1/19/2006
-
Dynavax Technologies Corporation Says Allergy Drug Meets Goal Of Phase 2/3 Trial
1/19/2006
-
Dynavax Technologies Corporation's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Efficacy In Phase 2/3 Clinical Trial
12/19/2005
-
Dynavax Technologies Corporation To Present Data On Phase 2/3 Clinical Trial Of HEPLISAV(TM) Hepatitis B Vaccine At ICAAC 2005
12/8/2005
-
Dynavax Technologies Corporation Announces Exercise Of Underwriters' Over-Allotment Option
11/10/2005
-
Dynavax Technologies Corporation's TOLAMBA(TM) Demonstrates Safety In Phase 1 Trial of Ragweed Allergic Children
11/8/2005
-
Dynavax Technologies Corporation Appoints Nancy L. Buc, Former FDA Chief Counsel, To Its Board Of Directors
11/3/2005
-
Dynavax Technologies Corporation Initiates US-Based Phase 1 Clinical Trial Of HEPLISAV(TM) Hepatitis B Vaccine In Dialysis Population
11/1/2005
-
Dynavax Technologies Corporation Announces Third Quarter 2005 Financial Results
10/28/2005
-
Dynavax Technologies Corporation To Webcast Presentations At Upcoming Healthcare Conferences
10/26/2005
-
Dynavax Technologies Corporation Announces Third Quarter 2005 Financial Results Conference Call And Webcast
10/20/2005